Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP2 | P11137 | 11/20 | 0.48 |
| ▸ | SIRT1 | Q96EB6 | 8/20 | 0.43 |
| ▸ | SIRT2 | Q8IXJ6 | 3/20 | 0.43 |
| ▸ | SIRT3 | Q9NTG7 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4319380 | 0.97 | MAP2 (0.47) | MAP2SIRT1SIRT2SIRT3MAPT | |
| SCHEMBL4317335 | 0.95 | MAP2 (0.50) | MAP2SIRT1SIRT2SIRT3 | |
| SCHEMBL4315896 | 0.84 | MAP2 (0.48) | MAP2SIRT1SIRT2SIRT3 | |
| SCHEMBL4313647 | 0.84 | ALDH1A1 (0.53) | MAPTALOX15MAPK1SMN1; SMN2 | |
| SCHEMBL4322534 | 0.82 | MAP2 (0.51) | MAP2SIRT1SIRT2SIRT3MAPT | |
| SCHEMBL2882120 | 0.81 | SIRT1 (0.38) | SIRT1SIRT2SIRT3MAPTALOX15 | |
| SCHEMBL4310041 | 0.81 | ALDH1A1 (0.52) | MAPTALOX15MAPK1SMN1; SMN2 | |
| SCHEMBL2876719 | 0.80 | ALOX15 (0.40) | SIRT1SIRT2SIRT3MAPTALOX15 | |
| SCHEMBL4311159 | 0.80 | MAP2 (0.51) | MAP2SIRT1SIRT2SIRT3MAPT | |
| SCHEMBL4313597 | 0.80 | MAP2 (0.44) | MAP2SIRT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090131494-A1 | Non-Nucleoside Reverse Transcriptase Inhibitors | MERCK SHARP & DOHME CORP. | 2009-05-21 | — | — | US | claimed |
| EP-1915055-A2 | NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS | Merck & Co., Inc. (US) | 2008-04-30 | — | — | EP | claimed |
| WO-2007021629-A2 | NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS | MERCK & CO., INC. (US) | 2007-02-22 | — | — | WO | claimed |
| US-20090131494-A1 | Non-Nucleoside Reverse Transcriptase Inhibitors | MERCK SHARP & DOHME CORP. | 2009-05-21 | — | — | US | disclosed |
| US-20090131494-A1 | Non-Nucleoside Reverse Transcriptase Inhibitors | MERCK SHARP & DOHME CORP. | 2009-05-21 | — | — | US | disclosed |
| US-20090131494-A1 | Non-Nucleoside Reverse Transcriptase Inhibitors | MERCK SHARP & DOHME CORP. | 2009-05-21 | — | — | US | disclosed |
| WO-2007021629-A2 | NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS | MERCK & CO., INC. (US) | 2007-02-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090131494-A1 | Non-Nucleoside Reverse Transcriptase Inhibitors | IDO1, IDO2, INMT | MAP2 1220/4885SIRT1 699/4885SIRT2 487/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.